Repeat

NCS Multistage Holdings, Inc. Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 7, 2024

HOUSTON, March 07, 2024 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. (Nasdaq: NCSM) (the “Company,” “NCS,” “we” or “us”), a leading provider of highly engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies, today announced its results for the quarter and year ended December 31, 2023.

Key Points: 
  • Total revenues were $35.2 million for the quarter ended December 31, 2023, a decrease of 12% compared to the fourth quarter of 2022.
  • Gross profit was $12.3 million, or a gross margin of 35%, for the fourth quarter of 2023, compared to $15.6 million, or 39%, for the fourth quarter of 2022.
  • Other income was $0.4 million for the fourth quarter of 2023 as compared to $1.4 million for the fourth quarter of 2022.
  • Consequently, we reversed our previously recorded litigation provision of $40.8 million during the fourth quarter of 2023.

Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS

Retrieved on: 
Tuesday, January 16, 2024

Challenges to develop effective therapeutics for ALS stem, in part, from the diverse, and poorly understood genetic background of the patients.

Key Points: 
  • Challenges to develop effective therapeutics for ALS stem, in part, from the diverse, and poorly understood genetic background of the patients.
  • Dewpoint leverages an aberration that occurs in ~97% of all ALS patients – independent of genetic background – to drive the discovery and development of a new, and potentially more effective class of therapeutics.
  • “Receiving the Target ALS grant is a tremendous honor and a significant validation for Dewpoint’s novel, therapeutic approach to target condensatopathies,” said Ameet Nathwani, CEO of Dewpoint Therapeutics.
  • Dr. Amy Easton, Sr. Director of Scientific Programs at Target ALS said "Target ALS is excited to fund the generation of in vivo target validation data to support development of Dewpoint Therapeutics’ clinical candidate for ALS.

Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference

Retrieved on: 
Saturday, January 6, 2024

Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.

Key Points: 
  • Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.
  • We also continue to expand access to imlifidase for highly sensitized kidney transplant patients through a new commercial partnership with NewBridge in the MENA region.
  • Management will be available for meetings in San Francisco during the J.P. Morgan Conference week, January 8-11, 2024.
  • Susan Noonan is coordinating the schedule on behalf of Hansa Biopharma and can be reached at [email protected] .

Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference

Retrieved on: 
Saturday, January 6, 2024

Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.

Key Points: 
  • Søren Tulstrup, President and CEO, Hansa Biopharma said: "Hansa enters 2024 in a strong position to successfully execute on our key priorities.
  • We also continue to expand access to imlifidase for highly sensitized kidney transplant patients through a new commercial partnership with NewBridge in the MENA region.
  • Management will be available for meetings in San Francisco during the J.P. Morgan Conference week, January 8-11, 2024.
  • Susan Noonan is coordinating the schedule on behalf of Hansa Biopharma and can be reached at [email protected] .

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Retrieved on: 
Monday, November 6, 2023

The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023. As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com.

Key Points: 
  • The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.
  • The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023.
  • As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com .
  • “Today the company is focused on the development of novel T cell immunotherapeutic candidates, which evolved out of that initial vaccine research.

NCS Multistage Holdings, Inc. Announces Third Quarter 2023 Results

Retrieved on: 
Monday, October 30, 2023

HOUSTON, Oct. 30, 2023 (GLOBE NEWSWIRE) -- NCS Multistage Holdings, Inc. (Nasdaq: NCSM) (the “Company,” “NCS,” “we” or “us”), a leading provider of highly engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies, today announced its results for the quarter ended September 30, 2023.

Key Points: 
  • Total revenues were $38.3 million for the quarter ended September 30, 2023, which was a decrease of 22% compared to the third quarter of 2022.
  • These results were impacted by lower activity levels in 2023 compared to the prior year.
  • Other income was $2.0 million for the third quarter of 2023 as compared to $0.6 million for the third quarter of 2022.
  • The Company will host a conference call to discuss its third quarter 2023 results and updated guidance on Tuesday, October 31, 2023, at 7:30 a.m. Central Time (8:30 a.m. Eastern Time).

QVC+ AND HSN+ REVEALS NEW FALL STREAMING PROGRAMMING HEADLINED BY ORIGINAL HOLIDAY MOVIE 'THE RECIPE FILES' STARRING ASHLEE SIMPSON

Retrieved on: 
Thursday, October 26, 2023

WEST CHESTER, Pa., Oct. 26, 2023 /PRNewswire/ -- The QVC+ and HSN+ streaming experience today announced its new fall streaming programming with a full slate of retailtainment to get viewers in a festive mood this holiday season. The announcement is headlined by "The Recipe Files," an original QVC+ holiday movie directed by Lindsay Hartley ("Passions," "Days of Our Lives") and starring singer-songwriter and actress Ashlee Simpson. In addition, several original debuts and new exclusive content will launch throughout the season featuring premier brands, fresh new products, and the people and stories behind them, presented by celebrities, influencers and interesting personalities.

Key Points: 
  • The announcement is headlined by "The Recipe Files," an original QVC+ holiday movie directed by Lindsay Hartley ("Passions," "Days of Our Lives") and starring singer-songwriter and actress Ashlee Simpson.
  • "The Recipe Files" is an original QVC+ holiday movie produced in collaboration with Nicely Entertainment, directed by Lindsay Hartley and starring singer-songwriter and actress Ashlee Simpson , Morgan Bradley and Doug Noble .
  • Will she solve it in time for the holidays or will her efforts be a recipe for disaster?
  • You can watch your favorite programs via the QVC+ and HSN+ streaming experience anytime with Video on Demand .

Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2023

Retrieved on: 
Wednesday, October 11, 2023

WARMINSTER, Pa., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that clinical data from the Company’s lead HBV focused asset, imdusiran (AB-729), an RNAi therapeutic, and preclinical data from its oral PD-L1 inhibitor program, will be highlighted in oral and poster presentations, including a late breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, taking place from November 10-14, 2023 in Boston, MA.

Key Points: 
  • Data Summary: Treatment with oral small-molecule PD-L1 inhibitors possessing liver-tropic pharmacokinetic profiles was associated with increased efficacy and tumor clearance in a novel humanized orthotopic HCC mouse model.
  • These data suggest that development of small-molecule PD-L1 inhibitors with biodistribution to the liver may provide benefit in the treatment of HCC.
  • Available data indicate that adding VBR to AB-729+NrtI does not result in significantly greater on- or post-treatment improvements in markers of active HBV infection vs AB-729+NrtI.
  • The poster presentations will available on Arbutus’ website on November 10, 2023 and can be accessed through the Publications section at https://www.arbutusbio.com/publications/ .

Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487

Retrieved on: 
Monday, October 9, 2023

LUND, Sweden, Oct. 9, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced high-level results from NICE-01, the first-in-human trial for HNSA-5487. Results showed the molecule was safe and well tolerated. Fast and complete depletion of immunoglobulin G (IgG) antibodies was observed at increasing doses in all subjects. Pharmacokinetics (PK) was in line with expectations and pharmacodynamics (PD) (efficacy on IgG cleavage) showed a fast and complete cleavage of IgG to F(ab')2- and Fc-fragments with increasing doses.

Key Points: 
  • LUND, Sweden, Oct. 9, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced high-level results from NICE-01, the first-in-human trial for HNSA-5487.
  • Fast and complete depletion of immunoglobulin G (IgG) antibodies was observed at increasing doses in all subjects.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "This is encouraging data as we continue to explore the potential for HNSA-5487 and better understand how this powerful, new enzyme could benefit patients and clinicians.
  • This analysis will serve as key input in determining the further clinical development program, including selection of indications.

Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487

Retrieved on: 
Monday, October 9, 2023

LUND, Sweden, Oct. 9, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced high-level results from NICE-01, the first-in-human trial for HNSA-5487. Results showed the molecule was safe and well tolerated. Fast and complete depletion of immunoglobulin G (IgG) antibodies was observed at increasing doses in all subjects. Pharmacokinetics (PK) was in line with expectations and pharmacodynamics (PD) (efficacy on IgG cleavage) showed a fast and complete cleavage of IgG to F(ab')2- and Fc-fragments with increasing doses.

Key Points: 
  • LUND, Sweden, Oct. 9, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced high-level results from NICE-01, the first-in-human trial for HNSA-5487.
  • Fast and complete depletion of immunoglobulin G (IgG) antibodies was observed at increasing doses in all subjects.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "This is encouraging data as we continue to explore the potential for HNSA-5487 and better understand how this powerful, new enzyme could benefit patients and clinicians.
  • This analysis will serve as key input in determining the further clinical development program, including selection of indications.